Cagrilintide

Cagrilintide (AM833) is a novel long-acting lipidated amylin analog that acts as a dual amylin and calcitonin receptor agonist. Developed for weight management and type 2 diabetes treatment, it shows superior weight loss potential when combined with semaglutide (CagriSema), with recent Phase 3 trials demonstrating up to 22.7% weight reduction.

• Superior Obesity Treatment
• Type 2 Diabetes Weight Management
• Sustained Weight Maintenance

FDA development candidate, extensive Phase 3 data, superior weight loss in combination with semaglutide, once-weekly convenience

Subcutaneous injection provides optimal bioavailability of lipidated amylin analog, targeting dual amylin and calcitonin receptors for satiety and metabolic effects

Peak plasma concentration: 2 days. Elimination half-life: 7.5 days. Largely cleared by: ~37.5 days.

Research protocols from published literature — not dosing recommendations.

• Semaglutide — Synergistic: CagriSema combination demonstrates enhanced weight loss (22.7% vs 16.1% semaglutide alone) and improved glycemic control through complementary GLP-1 and amylin pathways.
• Tirzepatide — Compatible: No known direct interactions. Both are effective weight loss agents with different mechanisms - cagrilintide targets amylin/calcitonin receptors while tirzepatide targets GLP-1/GIP receptors.
• Retatrutide — Use Caution: Both cause significant GI effects (gastroparesis, nausea). Cagrilintide (amylin agonist) and Retatrutide (triple GLP-1/GIP/glucagon agonist) have different mechanisms but compounded GI side effects create substantial risk. Not recommended without specialist supervision.
• Liraglutide — Compatible: Phase 2 trials show similar efficacy profiles with no adverse interactions. Both GLP-1 agonists and amylin analogs work through distinct satiety pathways.
• Insulin — Monitor Combination: Monitor glucose levels closely as cagrilintide affects gastric emptying and may alter insulin absorption timing. May require insulin dose adjustments in diabetic patients.
• Metformin — Compatible: Well-tolerated combination demonstrated in Phase 2/3 trials. No pharmacokinetic interactions observed between cagrilintide and metformin.
• SGLT2 Inhibitors — Compatible: Clinical trials included patients on SGLT2 inhibitors with no safety concerns. Both mechanisms complement each other for diabetes and weight management.
• Pramlintide — Avoid Combination: Both are amylin receptor agonists with overlapping mechanisms. Combination would provide no additional benefit and may increase risk of gastrointestinal side effects.
• Oral Contraceptives — Requires Timing: Delayed gastric emptying may affect absorption of oral contraceptives. Space administration by 1 hour before cagrilintide injection.

Supplies:

• Pre-filled pen injector (when approved)
• Bacteriostatic water (standard BAC water acceptable for <30 days use)
• Optional: 0.6% acetic acid to adjust pH to ~4.0 for optimal stability
• Alcohol swabs for injection site preparation
• Sharps disposal container

1. 1Reconstitute slowly down side of vial, swirl gently (don't shake)
2. 2Verify solution is clear - any cloudiness or particles indicates fibril formation, discard immediately
3. 3Store refrigerated (2-8°C), inspect for clarity before each injection
4. 4Allow to reach room temperature 15-30 minutes before injection
5. 5Inject subcutaneously in abdomen, thigh, or upper arm, rotating sites weekly

Week 1-2: Gastrointestinal adaptation period, mild nausea possible during dose escalation. Week 4-8: Early weight loss becomes apparent (2-5%), appetite reduction noticeable. Week 12-26: Significant weight loss acceleration (10-15%), improved satiety signals. Week 26+: Peak efficacy achieved (15-23% weight loss), sustained weight loss maintenance with continued therapy.

Most common side effects are gastrointestinal (nausea, vomiting, diarrhea) during initial weeks. Anti-cagrilintide antibodies develop in 46-73% of patients but do not affect efficacy. No clinically significant QT prolongation observed in thorough QT studies. Only 57.3% of patients achieved maximum 2.4 mg dose in REDEFINE 1 trial. Formulation must be maintained at acidic pH (3.5-4.5) to prevent fibril formation and deamidation. Reconstituted solutions should be inspected for cloudiness or particles before each use.

Most common side effects are gastrointestinal (nausea, vomiting, diarrhea) during initial weeks. Anti-cagrilintide antibodies develop in 46-73% of patients but do not affect efficacy. No clinically significant QT prolongation observed in thorough QT studies. Only 57.3% of patients achieved maximum 2.4 mg dose in REDEFINE 1 trial. Formulation must be maintained at acidic pH (3.5-4.5) to prevent fibril formation and deamidation. Reconstituted solutions should be inspected for cloudiness or particles before each use.

Cagrilintide should be stored at Store frozen at -20°C, protect from light, do not shake.